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steadily over time in overall visits, all-purpose prescribed drugs, and prescribed
drugs attributable to ADSD. Future studies are needed to assess trend patterns in
specific classes of anti-dementia drugs (e.g., memantine, cholinesterase inhibitor,
or donepezil/rivastigmine/gallantamine).
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OBJECTIVES: Here, we evaluated the effect of the Effexor (N06AX16) patent expiry
in Sweden. The aim was to see if adaptations, such as generic penetration, in-
creased new prescriptions, or switches from other SNRIs, could be seen when
evaluating all dispatches in the year before (2008) and after (2009) the patent expiry.
METHODS:We used the CEBRxA database, which combines data from the national
Swedish drug registry, with a public claims database for the South-West region of
Sweden, comprising around 1.5 million individuals. For the generic penetration
analysis, all prevalent patients were selected. For the longitudinal analysis, all
patients who had made at least 2 dispatches of any antidepressant (N06A*) were
selected and a 6 months washout-period was applied. Subsequently, all dispatches
were annotated, at the ATC level, as either new (no other antidepressants within
105 days), add-on (specific antidepressant dispatched both before and after), switch
(specific antidepressant dispatched before, but not after), or continuation (dis-
patched same ATC-code within 105 days). RESULTS: Of all N06AX16 dispatches in
2009, 81% corresponded to generic Venlafaxin, and the remaining 19% corre-
sponded to branded Effexor. However, the prevalent patient counts decreased from
12,467 in 2008, to 12,248 in 2009. This trend was opposite to that of other SNRIs;
generic Mirtazapine (N06AX11) and branded Cymbalta (N06AX21) both increased
by three and 10 percent, respectively. Amongst the incident population, only minor
differences were observed when comparing the proportion of dispatches with ev-
idence of a new treatment, switch or add-on, between 2008 and 2009 for N06AX16.
CONCLUSIONS: Al though generic penetration was quite efficient, we did not ob-
serve an increased proportion of patients switching to, or new prescriptions for,
generic Venlafaxin during 2009. This can to some extent be explained by the expiry
date on prescriptions, extending into 2009, while the decreasing prevalent patient
population suggests additional dimensionality.
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OBJECTIVES: Extended release (XR) and instant release (IR) quetiapine differ with
respect to e.g. dosing, titration, and plasma concentration profiles. This could re-
sult in differential XR and IR use in schizophrenia and bipolar disorder (BD). We
compared the use of XR and IR in a naturalistic, inpatient setting. METHODS: We
retrospectively collected registry data among patients discharged between June
2008-June 2010 from a Finnish psychiatric hospital. Patients with a schizophrenia
spectrum (SCZ; ICD-10 codes F20-F29) or a BD (F30-F31) diagnosis who used que-
tiapine in hospital were included in the study. Descriptive statistics and signifi-
cance tests of differences between groups were performed. To assess the profile of
XR- vs. IR-patients, logistic regressions were performed. RESULTS: Amongst 156
patients included (58% male), 43 used XR, 58 used IR, and 55 used both quetiapine
formulations; 102 patients (65%) were diagnosed with SCZ and 54 (35%) with BD; no
significant differences in diagnosis between quetiapine formulations. The mean
XR dose was significantly higher than that of IR (542mg versus 328mg; p0.001).
This was true also for the SCZ (XR: 593mg vs. IR: 338mg; p0.001) and BD (XR: 466mg
versus IR: 308mg; p0.009) subgroups. 48% of all IR-patients used a mean dose
200mg, compared to 2% of XR-patients. IR was combined with injectable antipsy-
chotic treatment whereas XR was not (12% vs. 0%; p0.019). XR was associated with
antipsychotic monotherapy to a higher extent than IR (44% vs. 28%; p0.08). In the
logistic regressions, XR use was significantly associated with decreasing age and
prior XR use; IR use was associated with e.g. substance abuse. CONCLUSIONS:
Among schizophrenia spectrum or bipolar disorder inpatients, quetiapine XR was
used in significantly higher doses than IR. Compared to XR, IR was more often
combined with other antipsychotics. Differential use of quetiapine formulations
seemed partly dependent on patient characteristics.
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OBJECTIVES: To describe the use of atypical antipsychotics (AA) among individuals
suffering from schizophrenia in a public managed healthcare system according to
material and social deprivation. METHODS: We conducted a population-based co-
hort study using a spatiotemporal information system built with Quebec adminis-
trative health data. For four consecutive 2-year periods from 1998-2005, a cohort of
inhabitants aged 18 years was built. Individuals were included in a cohort if they
had a diagnosis of schizophrenia recorded in the hospital registry or in the physi-
cian consultations database during the 2-year period and if they were covered by
the public drug plan during the year following the date of the 1st schizophrenia
diagnosis in the period. Material and social deprivation were measured using indi-
ces built at a geographical level. Individuals in the 1st and 5th quintiles were the
least and most deprived, respectively. Individuals were considered exposed to an
AA if they obtained such a drug in the year following the date of 1st schizophrenia
diagnosis. RESULTS: The proportion of individuals exposed to an AA in the year
following the diagnosis of schizophrenia increased from a low 44% (15,386/34,765)
in 1998-99 to a high 71% (25,555/35,771) in 2004-05. In terms of social deprivation,
the proportion of those exposed to an AA among the least deprived and the most
deprived were respectively 42% and 47% in 1998-99 and 67% and 73% in 2004-05. In
terms of material deprivation, these proportions ranged from 44% and 45% in
1998-99 to 69% and 72% in 2004-05. CONCLUSIONS: The proportion of individuals
exposed to AA has increased over the years 1998-2005, both among the least and
the most socially and materially deprived suggesting that the most deprived may
have a better access to AA. This may be due to free access to medication in Quebec’s
publicly managed healthcare system.
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OBJECTIVES: Epilepsy produces a significant burden on health care systems world-
wide. Focal epilepsy represents approximately 70% of all types of epilepsy. The
International League Against Epilepsy (ILAE) defined drug-resistant epilepsy in
2009 as a failure to achieve sustained seizure freedom, despite adequate trials of
two tolerated and appropriately chosen and used antiepileptic drug (AED) sched-
ules whether as monotherapies or in combination.The objective of this study was
to estimate the economic impact of AED resistance in Spanish patients with focal
epilepsy. METHODS: A multicentre, observational, cross-sectional, retrospective
study was conducted in Spain among a representative sample of adults with focal
epilepsy receiving at least two AEDs in combination, regardless of the seizure-free
status. Investigators were hospital-based general neurologists and epileptologists;
patients were consecutively included. Health resources utilisation data were col-
lected over a retrospective 12-month period. Estimation of direct costs was calcu-
lated by multiplying unitary costs (at National Health System- NHS- values for the
year 2010) by resource use from a NHS perspective. RESULTS: A total of 263 evalu-
able patients were analysed (out of 304 recruited patients, 86.5%). Responsiveness
to AED treatment was assessed: 71% of the patients were AED resistant, 24%
achieved seizure freedom and 5% were undefined. On average, resistant patients
received more AEDs compared to seizure-free patients: 2.7 versus 2.4, respectively
(p0.0037). Annual costs for AED resistant and seizure-free patients were 4419€
and 3228€ respectively (37% increase per patient/year; p0.0273). Drug costs (57%)
and hospitalisation costs (33%) accounted for 90% of the incremental costs of AED
resistant patients. CONCLUSIONS: Results suggest that drug resistant epilepsy is
associated with higher health care use and consequently with higher costs, thus
representing a considerable burden to the National Health System.
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OBJECTIVES: Rapid titration of extended-release quetiapine fumarate (quetiapine
XR) allows an effective dose to be reached by Day 2 in schizophrenia and bipolar
mania, and Day 4 in bipolar depression (versus Day 4 or later with quetiapine
immediate release [IR]). This study evaluates the impact of quetiapine XR on length
and cost of hospitalisation in patients with schizophrenia or bipolar disorder, com-
pared with quetiapine IR, using Premier Perspective™ Inpatient Hospital database
data.METHODS: Inpatient discharges classified within diagnosis-related group 430
(psychoses), prescribed either quetiapine XR or IR, were identified. Evaluable pa-
tients had an ICD-9 diagnosis of schizophrenia or bipolar disorder (295.0x, 296.0x,
296.1x, 296.4x, 296.5x, 296.6x, 296.7x or 296.8x). Impact of the XR formulation on
length and cost of hospitalisation was assessed using multiple logistic regression
(GENMOD procedure), adjusting for patient and hospital characteristics. The data
were not normally distributed, therefore log-transformed data were used.
RESULTS: In total, 30,429 discharges between January 1, 2008 and June 30, 2009
were analysed. GENMOD analyses showed that patients who received quetiapine
XR had significantly reduced hospitalisation length (10.7% estimated reduction,
p0.001) and cost (9.5% estimated reduction, p0.001), compared with patients
who received quetiapine IR. These rates correspond to -1.0 days (10.7% of 9.2 days)
and -US$531 (9.5% of US$5588) per patient, based on least squares mean estima-
tions of length and cost of hospitalisation in patients treated with quetiapine IR.
Evaluation of patient sub-populations indicated that the significant reduction in
length of hospitalisation for quetiapine XR versus IR was driven mainly by patients
with bipolar disorder, whereas the significant reduction in costs was driven mainly
by patients with schizophrenia. CONCLUSIONS: Inpatient use of quetiapine XR in
patients with schizophrenia or bipolar disorder is associated with significantly
reduced length and cost of hospitalisation, possibly due to the faster titration
schedule for quetiapine XR versus IR.
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